Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial.

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

The FDA has approved Dupixent as an add-on maintenance therapy for adults with inadequately controlled COPD and an eosinophilic phenotype.

The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with type 2 ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on ...

The US Food and Drug Administration (FDA) on Friday approved Dupixent (dupilumab) as an add-on maintenance treatment of ...